Durable near-complete response to Anti-PD-1 checkpoint immunotherapy in a refractory malignant solitary fibrous tumor of the pleura

James T. Boothe, G. Thomas Budd, Matthew B. Smolkin, Patrick C. Ma

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Solitary fibrous tumor of the pleura is a rare and usually benign primary neoplasm arising from mesenchymal cells of the submesothelial tissue. We present here the case of a patient diagnosed with CD34-positive advanced malignant solitary fibrous tumor of the pleura whose disease failed to respond to combination cytotoxic chemotherapy agents, but demonstrated a prompt near-complete response to checkpoint blockade treatment using the anti-programmed death (PD)-1 monoclonal antibody pembrolizumab, based on tumor molecular profiling revealing tumoral expression positivity for both programmed death-ligand 1 (PD-L1) and PD-1. The patient experienced minimal adverse effects from the treatment with durable favorable response lasting up to cycle 26.

Original languageEnglish (US)
Pages (from-to)998-1005
Number of pages8
JournalCase Reports in Oncology
Volume10
Issue number3
DOIs
StatePublished - Nov 16 2017

Fingerprint

Pleural Solitary Fibrous Tumor
Immunotherapy
Cytotoxins
Combination Drug Therapy
Neoplasms
Monoclonal Antibodies
Ligands
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

@article{42d70c20c54447fd8f23e02928d131e8,
title = "Durable near-complete response to Anti-PD-1 checkpoint immunotherapy in a refractory malignant solitary fibrous tumor of the pleura",
abstract = "Solitary fibrous tumor of the pleura is a rare and usually benign primary neoplasm arising from mesenchymal cells of the submesothelial tissue. We present here the case of a patient diagnosed with CD34-positive advanced malignant solitary fibrous tumor of the pleura whose disease failed to respond to combination cytotoxic chemotherapy agents, but demonstrated a prompt near-complete response to checkpoint blockade treatment using the anti-programmed death (PD)-1 monoclonal antibody pembrolizumab, based on tumor molecular profiling revealing tumoral expression positivity for both programmed death-ligand 1 (PD-L1) and PD-1. The patient experienced minimal adverse effects from the treatment with durable favorable response lasting up to cycle 26.",
author = "Boothe, {James T.} and Budd, {G. Thomas} and Smolkin, {Matthew B.} and Ma, {Patrick C.}",
year = "2017",
month = "11",
day = "16",
doi = "10.1159/000484041",
language = "English (US)",
volume = "10",
pages = "998--1005",
journal = "Case Reports in Oncology",
issn = "1662-6575",
number = "3",

}

Durable near-complete response to Anti-PD-1 checkpoint immunotherapy in a refractory malignant solitary fibrous tumor of the pleura. / Boothe, James T.; Budd, G. Thomas; Smolkin, Matthew B.; Ma, Patrick C.

In: Case Reports in Oncology, Vol. 10, No. 3, 16.11.2017, p. 998-1005.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Durable near-complete response to Anti-PD-1 checkpoint immunotherapy in a refractory malignant solitary fibrous tumor of the pleura

AU - Boothe, James T.

AU - Budd, G. Thomas

AU - Smolkin, Matthew B.

AU - Ma, Patrick C.

PY - 2017/11/16

Y1 - 2017/11/16

N2 - Solitary fibrous tumor of the pleura is a rare and usually benign primary neoplasm arising from mesenchymal cells of the submesothelial tissue. We present here the case of a patient diagnosed with CD34-positive advanced malignant solitary fibrous tumor of the pleura whose disease failed to respond to combination cytotoxic chemotherapy agents, but demonstrated a prompt near-complete response to checkpoint blockade treatment using the anti-programmed death (PD)-1 monoclonal antibody pembrolizumab, based on tumor molecular profiling revealing tumoral expression positivity for both programmed death-ligand 1 (PD-L1) and PD-1. The patient experienced minimal adverse effects from the treatment with durable favorable response lasting up to cycle 26.

AB - Solitary fibrous tumor of the pleura is a rare and usually benign primary neoplasm arising from mesenchymal cells of the submesothelial tissue. We present here the case of a patient diagnosed with CD34-positive advanced malignant solitary fibrous tumor of the pleura whose disease failed to respond to combination cytotoxic chemotherapy agents, but demonstrated a prompt near-complete response to checkpoint blockade treatment using the anti-programmed death (PD)-1 monoclonal antibody pembrolizumab, based on tumor molecular profiling revealing tumoral expression positivity for both programmed death-ligand 1 (PD-L1) and PD-1. The patient experienced minimal adverse effects from the treatment with durable favorable response lasting up to cycle 26.

UR - http://www.scopus.com/inward/record.url?scp=85040169333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040169333&partnerID=8YFLogxK

U2 - 10.1159/000484041

DO - 10.1159/000484041

M3 - Article

AN - SCOPUS:85040169333

VL - 10

SP - 998

EP - 1005

JO - Case Reports in Oncology

JF - Case Reports in Oncology

SN - 1662-6575

IS - 3

ER -